<DOC>
	<DOCNO>NCT01785108</DOCNO>
	<brief_summary>The objective study - evaluate safety influence treatment GAD-Alum ( Diamyd ) combine Vitamin D Ibuprofen preservation residual insulin secretion recently diagnose Type 1 Diabetes - evaluate mention treatment influence immune system subject interact viral infection - evaluate safety influence treatment double dose GAD-Alum ( Diamyd ) plus Vitamin D immune system , viral infection , preservation residual insulin secretion recently diagnose Type 1 Diabetes</brief_summary>
	<brief_title>DIABGAD - Trial Preserve Insulin Secretion Type 1 Diabetes Using GAD-Alum ( Diamyd ) Combination With Vitamin D Ibuprofen</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Aluminum sulfate</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Main Male female patient 10 18 year age Insulin dependent Type 1 Diabetes mellitus diagnose within previous 4 month time screen Fasting Cpeptide level time screen equal 0.12 nmol/L Elevated GAD65 antibody ( GADA ) time screen Main Treatment immunosuppressant , continuous antiinflammatory drug , Vitamin D antidiabetic medication insulin A history certain disease condition ( e.g . anemia , HIV , epilepsy , head trauma , neurological disease cerebrovascular accident , alcohol drug abuse etc ) Treatment vaccine within 4 month prior first plan administration GADAlum/placebo plan treatment vaccine 4 month last injection GADAlum/Placebo , include influenza vaccine Participation clinical trial new chemical entity within previous 3 month Pregnancy plan pregnancy within 1 year last GADAlum/placebo dose Presence associate serious disease condition opinion investigator make patient noneligible study</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diamyd</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Juvenile Diabetes</keyword>
	<keyword>Diabetes type 1</keyword>
	<keyword>Autoimmune Diabetes</keyword>
	<keyword>Insulin dependent Diabetes</keyword>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Type 1 diabetes mellitus</keyword>
	<keyword>rhGAD65</keyword>
	<keyword>GAD</keyword>
	<keyword>GAD65</keyword>
	<keyword>GAD-alum</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus , Type 1</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Ibuprofen</keyword>
</DOC>